emraclidine emraclidine emraclidine (developmental code name cvl-231) is an investigational antipsychotic for the treatment of both schizophrenia and alzheimer’s disease psychosis developed by cerevel therapeutics. as of february 2023, it is in phase ii of clinical trial. emraclidine is a positive allosteric modulator that selectively targets the muscarinic acetylcholine receptor m4 subtype. the m4 receptor subtype is expressed in the striatum of the brain, which plays a key role in regulating acetylcholine and dopamine levels. an imbalance of these neurotransmitters has been linked to psychotic symptoms in schizophrenia. unlike other muscarinic receptors, m4 receptor subtypes are selectively expressed in the striatum and activation of these receptors has been shown to indirectly regulate dopamine levels without blocking d2/d3 receptors, which may lead to unwanted motor side effects seen in current antipsychotics. emraclidineidentifiers iupac name 1-(2,4-dimethyl-5,7-dihydropyrrolopyridin-6-yl)-2-azetidin-3-yl]ethanone cas number2170722-84-4pubchem cid140830653chemspider114856397uniij241y80eeokeggd12468chemical and physical dataformulac20h21f3n4omolar mass390.410 g·mol−13d model (jsmol)interactive image smiles cc1=cc(=nc2=c1cn(c2)c(=o)cc3cn(c3)c4=cc(=nc=c4)c(f)(f)f)c inchi inchi=1s/c20h21f3n4o/c1-12-5-13(2)25-17-11-27(10-16(12)17)19(28)6-14-8-26(9-14)15-3-4-24-18(7-15)20(21,22)23/h3-5,7,14h,6,8-11h2,1-2h3key:dtcznkwbdtxebs-uhfffaoysa-n